

65

M

2022/23

HALF-YEAR REPORT as at 31 March 2023

Significant events · Interim Group management report · Consolidated income statements · Consolidated statements of comprehensive income · Consolidated statements of the financial position (balance sheet) · Consolidated statements of changes in equity · Consolidated cash flow statements · Selected notes to the consolidated financial statements · Events after the end of the quarter · Contact · Financial calendar

B·R·A·I·N

ABOUT BRAIN

BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).

Through its own R&D activities, the Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 49.5 million in the fiscal year 2021/22.

CONTENTS

04 – 05	Significant events 1 January 2023 to 31 March 2023
06 – 09	Interim Group management report 1 October 2022 to 31 March 2023
10	Consolidated income statements [unaudited] 1 October 2022 to 31 March 2023 and for 1 January 2023 to 31 March 2023
11	Consolidated statements of comprehensive income [unaudited] 1 October 2022 to 31 March 2023 and for 1 January 2023 to 31 March 2023
12	Consolidated statements of the financial position (balance sheet) [unaudited] 31 March 2023
13	Consolidated statements of changes in equity [unaudited] 1 October 2022 to 31 March 2023
14	Consolidated cash flow statements [unaudited] 1 October 2022 to 31 March 2023
15 – 17	Selected notes to the consolidated financial statements 1 October 2022 to 31 March 2023
18	Contact, Financial calendar, disclaimer

SIGNIFICANT EVENTS

1 January 2023 to 31 March 2023

Akribion Genomics will prioritize the development of therapeutic applications within its CRISPR technology platform

BRAIN Biotech AG announced its intent to prioritize the development of the genome-editing activities bundled under the brand name Akribion Genomics on therapeutic applications, including applications in oncology. The mode of action of the nucleases selected for this purpose allows both the targeted cell enrichment and depletion by selective disruption. Due to the novel mode of action the nuclease G-dase E™ (previously termed "BEC") is also primed for applications in therapeutics such as the field of oncology.

BRAIN Biotech AG and AMSilk cooperate to develop high-performance bio-based protein fibers

As part of a strategic collaboration, BRAIN Biotech AG and AMSilk are combining their expertise to drive the development of high-performance fibers for the performance materials market. Bio-fabricated products hold enormous potential as sustainable material solutions for the future. New developments, such as those currently being developed by BRAIN Biotech AG and AMSilk, could revolutionize the performance materials market. Petroleum-based textile fibers made of polyethylene or polyamide, well known to be a main source of microplastics as well as causing the unsustainable disposal of old clothes in landfills.

BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères

BRAIN Biotech AG announced the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project's viability and economics of a natural sweetener alternative based on the molecule Brazzein. BRAIN owns the proprietary production technology for the molecule and will look to establish new partnerships on this program

BRAIN Biotech AG and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment

BRAIN Biotech AG announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA

oncology company committed to more effectively treating cancer using RNA therapeutics. The objective of the JDA is to co-develop a platform technology that combines a Class 2 CRISPR nuclease, the cell-killing G-dase E, developed by BRAIN Biotech's Akribion Genomics unit with TransCode's TTX nucleic acid delivery platform for the treatment of cancer.

TransCode's proprietary TTX platform is designed to enable systemic delivery of targeted nucleic acid-based therapeutics to tumors and metastases. Akribion Genomics' proprietary nuclease is designed to seek out selective genomic characteristics based on the existence of specific RNA biomarkers within target cells. Combining these technologies could unlock the potential of CRISPR-like cell targeting approaches for the treatment of cancer.

INTERIM GROUP MANAGEMENT REPORT

1 October 2022 to 31 March 2023

I. GROUP BASIS AND GENERAL CONDITIONS

The remarks made in the consolidated financial statements for the financial year ending 30 September 2022 about the Group's basis and general conditions continue to be applicable.

II. ECONOMIC AND BUSINESS REPORT

1. Results of operations

In the first six months of the 2022/2023 financial year, the BRAIN Biotech Group generated revenue of € 27.2 million compared to € 23.3 million in the same period of the previous year, which represents growth of 16.8 %. On an organic basis (in other words, excluding Breatec for the first four months and L.A. Schmitt GmbH for the previous year), revenue rose by 8.2%.

Revenue in the second quarter of 2022/23 amounted to € 13.5 million. This corresponds to an increase of 3.0 % compared to the second quarter of the previous year. Other income decreased by € 0.1 million to € 0.4 million. Total operating performance (revenue, research and development grant revenue, changes in inventories, and other income) in the first six months of the financial year rose by € 3.9 million (16.0 %) year-on-year, from € 24.2 million to € 28.1 million.

BRAIN Biotech AG announced at the Capital Markets Day on 27 February 2023 that it would be changing its reporting structure to three segments plus the holding company with the publication of the half-year figures. This is aligned with the already implemented operational leadership of the Group and further increases transparency for the capital market. The following changes have been made in the segment reporting compared to the consolidated financial statements as at 30 September 2022. The composition of the "BioIndustrial" segment remained unchanged, with the exception of the sale of L.A. Schmitt per 30 September 2022, and was renamed to "BioProducts". From the "BioScience" segment the business unit "BioIncubator" and "BRAIN Biotech Holding" have been excluded and are presented separately going forward. The BioScience segment continues to include the activities of BRAIN Biotech Zwingenberg and AnalytiCon Discovery. The previous year's figures were adjusted accordingly.

Revenue generated by the "BioProducts" segment reported growth of 19.0 %, from € 17.5 million to € 20.9 million, in the reporting period. In the second quarter of the financial year, revenue amounted to € 10.2 million. This corresponds to an increase of € 0.1 million, or 1.0 %, compared with the same quarter of the previous year. Adjusted EBITDA deteriorated from € 2.6 million to € 2.2 million in the first six months. The weaker operating momentum in the

second quarter is mainly due to production interruptions and operational pre-production costs in connection with the commissioning of the second large-scale fermenter at Biocatalysts Ltd. In addition, inflation-driven labour and pre-product costs can only be passed on to end customers with a certain time lag in some cases.

The "BioScience" segment generated revenue of € 6.1 million in the reporting period, corresponding to an increase of € 0.4 million or 6.5 % over the prior-year period. This growth mainly reflected a higher number of contracts signed for Tailor-Made Solutions projects. The adjusted EBITDA deteriorated from € 0.4 million in the same period of the previous year to € -0.0 million. The main drivers for this are increasing investments in personnel and higher other expenses such as increased marketing and sales expenses.

The "BioIncubator" segment generated revenue of € 0.2 million in the reporting period. R&D Grant revenue, generated by research funding from the German Federal Ministry of Education and Research, was slightly higher than the previous year's figure of € 0.1 million at € 0.2 million. The adjusted EBITDA is mainly driven by the ongoing investments into the CRISPR technology platform under the brand name Akribion Genomics and amounts to € -1.5 million in the first six months of the financial year. This is above the previous year's investment in BioIncubator projects of € -1.2 million.

The "BRAIN Biotech Holding" segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities. The adjusted EBITDA of the segment amounted to € -1.6 million and is constant at the previous year's level.

The adjusted Group EBITDA deteriorated by € 1.1 million from € 0.2 million in the previous year to € -0.9 million in the first six months of the 2022/23 financial year. This reflects the weaker adjusted EBITDA of € -0.5 million in the second quarter compared to € 0.5 million in the same quarter of the previous year. The main reasons for this were, as described above, start-up costs for the production expansion in fermentation and investments in personnel as well as investments in the BioIncubator.

The net financial result was € -1.1 million compared to € -0.9 million in the same period of the previous year. The increase in financial expenses from € -0.3 million to € -0.6 million is mainly due to interest expenses and the subsequent valuation of the put/call option liability for the acquisition of minority interests in Biocatalysts Ltd. As a result, the consolidated result before taxes deteriorated from € -3.6 million in the same period of the previous year to € -4.6 million in the current period.

Undiluted (basic) and diluted earnings per share during the first six months of the financial year amounted to € -0.22, compared with € -0.18 in the prior-year period.

The following table shows the reconciliation of unadjusted EBITDA to adjusted EBITDA.

€ thousand	6M 2022/23	6M 2021/22
EBITDA	-1,349	-725
Share-based employee compensation	-434	-528
Acquisition and integration costs incurred in the expansion of the BRAIN Biotech Group	0	-417
Adjusted EBITDA	-915	220

2. Net assets

Non-current assets decreased from € 47.6 million as at 30 September 2022 to € 46.5 million as at 31 March 2023 driven by depreciation of fixed assets and amortization of intangible assets.

Current assets decreased from € 30.4 million to € 28.0 million. This reduction is due to lower other current assets resulting from the receipt of the purchase price for the sale of L.A. Schmitt GmbH. In addition, trade receivables were lower compared to the last balance sheet date. Cash and cash equivalents, on the other hand, increased by € 0.7 million from € 8.4 million to € 9.2 million.

Equity decreased from € 34.2 million as at 30 September 2022 to € 29.9 million as at 31 March 2023. This is mainly driven by the negative result for the period. No capital measures were implemented during the reporting period.

The increase in non-current liabilities from € 22.4 million to € 24.2 million is due to an increase in long-term financial liabilities. Current liabilities decreased from € 21.4 million to € 20.4 million. The main reason for this is a net effect of (i) lower trade payables and reduced other liabilities, and (ii) an increase in current financial liabilities, as a result of drawing a short-term loan of € 3.0 million from an existing loan facility in the second quarter of the financial year.

3. Financial position

The Group's gross cash flow in the reporting period amounted to € -2.8 million, compared with € -2.2 million in the previous year.

Cash flow from operating activities deteriorated significantly compared with the same period of the previous year, from € -1.1 million to € -5.6 million. This decline is mainly attributable to the lower EBITDA operating result as well as a higher cash outflow from the change in trade payables and other liabilities.

Cash flow from investing activities in the first six months of the current financial year amounted to € 1.7 million compared to € -6.6 million in the prior-year period. The cash flow from investing activities is positively influenced by the receipt of the purchase price from the sale of L.A. Schmitt GmbH but also includes investments in fixed assets. These investments were lower than in the same period of the previous year.

Cash flow from financing activities, which in the reporting period mainly reflects the cash inflow from increasing financial liabilities, amounted to € 4.6 million compared to € -0.5 million in the previous year.

Compared to 30 September 2022, cash and cash equivalents increased from € 8.4 million to € 9.2 million, which is attributable to the combined aforementioned effects.

III. SIGNIFICANT OPPORTUNITIES AND RISKS

For a presentation of the risk management system and of potential opportunities and risks, please refer to the remarks on pages 94 ff. of the 2021/22 annual report of BRAIN Biotech AG.

Supply chains have proved to be largely stable despite the constraints in global logistics, although long delivery times for certain products have already had a dampening effect on the half-year results in the BioProducts segment due to the tight supply situation. Almost the entire global economy is currently influenced by high inflationary dynamics for raw materials, intermediate products as well as salary and service costs. In some cases, higher salary and input product costs can only be passed on to end customers with a certain time lag. In addition, a general slowdown in economic momentum poses a further challenge for the corporate sector. The general financing situation and financing conditions have deteriorated in particular for growth companies.

Nevertheless, from today's perspective and assuming no unforeseeable extraordinary events, BRAIN Biotech AG does not expect any significant changes compared to the opportunities and risks presented in the 2021/22 annual report.

Risks pursuant to Section 91 (2) of the German Stock Corporation Act (AktG) that might comprise going concern risks for the BRAIN Biotech Group are not identifiable at present.

IV. OUTLOOK

Compared to the outlook report presented on page 93 of the 2021/22 annual report, no significant changes are identifiable concerning the business outlook, apart from those relating to the development of the new genome editing tool of BRAIN Biotech AG. As such, the forecast remains unchanged, except for the elimination of the investments in this project. Despite the continuing strained supply chain situation in selected areas and the high inflationary dynamics, BRAIN Biotech AG is confident that it will be able to achieve the qualitative targets it has set for this financial year.

CONSOLIDATED INCOME STATEMENTS [UNAUDITED]

1 October 2022 to 31 March 2023 and 1 January 2023 to 31 March 2023

€ thousand	6M 2022/23	6M 2021/22	Q2 2022/23	Q2 2021/22
Revenue	27,170	23,267	13,476	13,090
Research and development grant revenue	389	359	147	145
Change in inventories of finished goods and work in progress	135	107	762	324
Other income	399	480	211	219
	28,093	24,213	14,596	13,778
Cost of materials				
Cost of raw materials and supplies, and purchased merchandise	-12,455	-9,428	-6,808	-5,601
Cost of purchased services	-540	-684	-241	-350
	-12,995	-10,112	-7,048	-5,952
Personnel expenses				
Wages and salaries	-9,232	-8,253	-4,720	-4,325
Share-based employee compensation	-434	-528	-118	-267
Social security and post-employment benefit costs	-1,730	-1,578	-853	-788
	-11,396	-10,359	-5,691	-5,380
Other expenses	-5,051	-4,467	-2,503	-2,524
	-1,349	-725	-646	-79
EBITDA				
Depreciation, amortization and impairment	-2,216	-2,058	-1,108	-1,081
	-3,565	-2,783	-1,754	-1,160
Operating result (EBIT)				
Share of profit or loss from equity-accounted investments	-998	-1,218	-581	-517
Finance income	551	654	547	383
Finance costs	-610	-290	-434	-75
	-1,057	-854	-469	-209
	-4,622	-3,636	-2,222	-1,369
Pretax result for the reporting period				
Income tax expense/income				
a) Current tax expense	-166	-269	-18	-132
b) Deferred tax expense (-)/ income (+)	180	157	88	84
	14	-112	71	-48
	-4,608	-3,748	-2,152	-1,418
Result for the reporting period				
of which attributable to:				
Non-controlling interests	189	207	115	179
Shareholders of BRAIN Biotech AG	-4,797	-3,955	-2,267	-1,597
Earnings per share, basic (undiluted)	-0.22	-0.18	-0.10	-0.07
Number of shares taken as basis	21,847,495	21,847,495	21,847,495	21,847,495
Earnings per share, diluted	-0.22	-0.18	-0.10	-0.07
Number of shares taken as basis	21,847,495	21,847,495	21,847,495	21,847,495

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

[UNAUDITED] 1 October 2022 to 31 March 2023 and 1 January 2023 to 31 March 2023

€ thousand	6M 2022/23	6M 2021/22	Q2 2022/23	Q2 2021/22
Result for the reporting period	-4,608	-3,748	-2,152	-1,418
of which attributable to:				
Non-controlling interests	189	207	115	179
Shareholders of BRAIN Biotech AG	-4,797	-3,955	-2,267	-1,597
Other comprehensive income:				
Items that will be reclassified subsequently to profit or loss				
Differences from the translation of foreign-currency financing instruments	10	-95	-44	16
Differences from the translation of foreign operations	-183	465	180	-66
Other comprehensive income (loss), net	-173	370	136	-50
Consolidated total comprehensive income (loss)	-4,782	-3,378	-2,016	-1,468
of which attributable to:				
Non-controlling interests	180	273	147	226
Shareholders of BRAIN Biotech AG	-4,961	-3,652	-2,162	-1,695

CONSOLIDATED STATEMENTS OF THE FINANCIAL POSITION (BALANCE SHEET) [UNAUDITED] 31 March 2023

€ thousand	31.03.2023	30.09.2022
Non-current assets		
Intangible assets	15,835	16,764
Property, plant and equipment	28,606	28,737
Equity-accounted investments	1,903	1,938
Other non-current assets	155	168
	46,499	47,608
Current assets		
Inventories	9,666	9,661
Trade receivables	7,244	8,036
Other current assets	1,266	3,811
Other financial assets	680	435
Cash and cash equivalents	9,156	8,443
	28,012	30,384
ASSETS	74,511	77,992
Equity		
Subscribed capital	21,847	21,847
Capital reserves	93,060	92,660
Retained earnings	-89,994	-85,197
Other reserves	164	328
	25,077	29,638
Non- controlling interests	4,789	4,610
Total equity	29,866	34,248
Non-current liabilities		
Deferred tax	3,082	3,292
Provisions for post-employment benefits for employees	1,153	1,153
Financial liabilities	17,674	15,435
Other liabilities	1,689	1,709
Deferred income	644	766
	24,243	22,356
Current liabilities		
Provisions	525	654
Current tax liabilities	139	190
Financial liabilities	10,985	8,437
Prepayments received	22	13
Trade payables	4,220	6,754
Other liabilities	2,631	3,350
Deferred income	1,880	1,990
	20,402	21,388
EQUITY AND LIABILITIES	74,511	77,992

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

[UNAUDITED] 1 October 2022 to 31 March 2023

1 October 2021 to 31 March 2022	Interests of shareholders of BRAIN Biotech AG					Non-controlling interests	
	Subscribed capital	Capital reserves	Retained earnings	Other reserves	Total		Total
€ thousand	Total			Currency translation			
Balance at 30 September 2021	21,847	95,890	-79,509	555	38,783	3,044	41,828
Total comprehensive income (loss) 01.10.2021 - 31.03.2022			-3,955	303	-3,652	273	-3,378
Addition of non-controlling interests part of the acquisition of fully consolidated Group companies						1,621	1,621
Addition of liability from put/call agreement relating to the acquisition of non-controlling interests in fully consolidated Group companies		-5,199			-5,199		-5,199
Transfers due to employee share scheme		350			350		350
Balance at 31 March 2022	21,847	91,041	-83,464	858	30,282	4,938	35,221

1 October 2022 to 31 March 2023	Interests of shareholders of BRAIN Biotech AG					Non-controlling interests	
	Subscribed capital	Capital reserves	Retained earnings	Other reserves	Total		Total
€ thousand	Total			Currency translation			
Balance at 30 September 2022	21,847	92,660	-85,197	328	29,638	4,610	34,248
Total comprehensive income (loss) 01.10.2022 - 31.03.2023			-4,797	-165	-4,961	180	-4,782
Transfers due to employee share scheme		399			399		399
Balance at 31 March 2023	21,847	93,060	-89,994	164	25,077	4,789	29,866

CONSOLIDATED CASH FLOW STATEMENTS [UNAUDITED]

1 October 2022 to 31 March 2023

€ thousand	6M 2022/23	6M 2021/22
Net profit (loss) for the period, after tax	-4,608	-3,748
Depreciation and amortization	2,216	2,058
Deferred tax expense (income)	-180	-157
Conversion of deferred income into revenue	-1,286	-1,137
Income from the release of provisions and liabilities	-47	-186
Share of profit or loss from equity-accounted investments	998	1,218
Other non-cash expenses (income)	111	-221
Losses on disposals of intangible assets and property, plant and equipment	-2	-27
Gross cash flow	-2,798	-2,201
Change in trade receivables	812	-294
Change in inventories	-20	-959
Change in tax assets and liabilities	-48	96
Change in other assets and financial assets	-745	-291
Change in trade payables	-2,399	1,072
Change in prepayments received	9	186
Change in provisions and other liabilities	-1,158	-27
Additions from deferred income	788	1,355
Cash flow from operating activities	-5,557	-1,062
Net cash outflows for acquisitions of companies (less cash and cash equivalents acquired)	0	-3,096
Net cash inflows from disposals of companies (less cash and cash equivalents divested)	3,040	0
Payments to acquire intangible assets	-8	-188
Payments to acquire property, plant and equipment	-1,273	-2,211
Net proceeds from other non-current assets	7	7
Investments in equity-accounted shareholdings	-114	-1,173
Proceeds from disposal of property, plant and equipment	41	39
Cash flow from investing activities	1,693	-6,623
Proceeds from borrowings	5,792	328
Repayments of borrowings	-1,184	-840
Cash flow from financing activities	4,607	-512
Net change in cash and cash equivalents	743	-8,197
Cash and cash equivalents at start of reporting period	8,443	24,545
Exchange-rate-related change in cash	-30	93
Cash and cash equivalents at end of reporting period	9,156	16,441
Cash flows from operating activities include:		
Interest paid	274	259
Interest received	5	5
Income taxes paid	19	73
Income taxes received	0	0

SELECTED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS [UNAUDITED]

1 October 2022 to 31 March 2023

Accounting policies

The Group interim report of BRAIN Biotech AG as at 31 March 2022 was prepared on the basis of IAS 34 (Interim Financial Reporting). All International Financial Reporting Standards (IFRS) that were binding as at the reporting date and had been adopted into European law by the European Commission were applied. The interim consolidated financial statements have not been audited in accordance with Section 317 of the German Commercial Code (HGB), nor have they been reviewed by an auditor.

Segment reporting

The following changes have been made in the Segment reporting compared to the consolidated financial statements as at 30 September 2022. The composition of the **"BioIndustrial"** segment remained unchanged, with the exception of the sale of L.A. Schmitt per 30 September 2022, and was renamed to **"BioProducts"**. From the **"BioScience"** segment the business unit **"BioIncubator"** and **"BRAIN Biotech Holding"** have been excluded and are presented separately going forward. The BioScience segment continues to include the activities of BRAIN Biotech Zwingenberg and AnalytiCon Discovery. The previous year's figures were adjusted accordingly. The segment results¹ are presented as follows.

€ thousand	BioProducts		BioScience		BioIncubator		BRAIN Biotech Holding		Reconciliation		Group	
	6M 22/23	6M 21/22	6M 22/23	6M 21/22	6M 22/23	6M 21/22	6M 22/23	6M 21/22	6M 22/23	6M 21/22	6M 22/23	6M 21/22
Total revenue	20,853	17,525	6,145	5,769	175	0	0	0	-3	-27	27,170	23,267
Of which: Revenue generated with other segments	3	27	0	0	0	0	0	0	-3	-27	0	0
Of which: Revenue generated with external customers	20,849	17,498	6,145	5,769	175	0	0	0	0	0	27,170	23,267
R&D grant revenue ² [external]	46	46	157	279	186	34	0	0	0	0	389	359
Changes in inventories ³	-12	64	147	43	0	0	0	0	0	0	135	107
Other income	171	118	237	372	0	0	0	0	-9	-10	399	480
Total operating performance	21,059	17,753	6,686	6,463	361	34	0	0	-13	-37	28,093	24,213
EBITDA	2,131	2,388	-180	198	-1,470	-1,200	-1,823	-2,153	-7	43	-1,349	-725
Adjusted EBITDA	2,165	2,566	-9	389	-1,470	-1,200	-1,595	-1,577	-7	43	-915	220
Operating result (EBIT)	606	990	-871	-462	-1,470	-1,200	-1,823	-2,153	-7	43	-3,565	-2,783
Finance income											551	654
Result from equity-accounted investments											-998	-1,218
Finance costs											-610	-290
Result before taxes											-4,622	-3,636

¹ After partial elimination within the segment

² Research and development grant revenue

³ Changes in inventories of finished goods and work in progress

Number of employees in the Group⁴

Average for the reporting period	6M 2022/23	FY 2021/22
Total employees, of which	309	309
Salaried employees	301	284
Industrial employees	8	24

The BRAIN Biotech Group also employees scholarships/grant holders (4, FY 21/22: 1), temporary employees (16, FY 21/22: 12) and trainees (5, FY 21/22: 6).

Related party transactions

During the first six months of the 2022/23 financial year, no new transactions with related parties were concluded that were not already presented in the financial statements as at 30 September 2022, and that had a significant effect on the financial position and performance of the BRAIN Biotech Group.

EVENTS AFTER THE END OF THE QUARTER

BRAIN Biotech AG fully acquires Biocatalysts Ltd.

BRAIN Biotech AG has acquired the final two minority interests in Biocatalysts Ltd. Biocatalysts is now fully owned by BRAIN Biotech AG and will form the core of the Group's ambitious growth strategy to create a global multi-niche enzyme company.

At the Capital Markets Day on 27 February 2023, BRAIN Biotech AG had announced the bundling of the entire product business under the leadership of Biocatalysts as the OneBio-Products Strategy. In the coming months, the BRAIN Biotech Group will transfer the companies Breatec B.V., Biosun Biochemicals Inc. and WeissBioTech GmbH to Biocatalysts in order to complete the reorganisation of the BioProducts segment.

⁴ Excluding the members of the parent company's Management Board and the subsidiaries' managing directors

Responsibility statement

According to the best of our knowledge and in accordance with applicable principles for interim reporting, the interim consolidated financial statements convey a true and fair view of the Group's financial position and performance. The interim Group management report conveys a true and fair view of the development and course of business operations as well as of the Group's position, and appropriately presents the significant opportunities and risks entailed in the Group's future development during the remaining months of the financial year.

Zwingenberg, 25 May 2023

The Management Board



Adriaan Moelker



Michael Schneiders

CONTACT

You can find the relevant contact persons via this address:

Investor Relations
ir@brain-biotech.com
+49 (0) 6251/9331-0

FINANCIAL CALENDAR

25.05.2023 Publication of the quarterly statement
as at 31.03.2023 (6M)

30.08.2023 Publication of the quarterly statement
as at 30.06.2023 (9M)

17.01.2024 Publication of the annual report
as at 30.09.2023 (12M)

28.02.2024 Publication of the quarterly statement
as at 31.12.2023 (3M)

12.03.2024 Annual General Meeting

Disclaimer

This interim report might contain certain forward-looking statements that are based on current assumptions and forecasts made by the management of the BRAIN Biotech Group and other currently available information. Various known and unknown risks and uncertainties as well as other factors can cause the company's actual results, financial position, development or performance to diverge significantly from the estimates provided here. BRAIN Biotech AG does not intend and assumes no obligation of any kind to update such forward-looking statements and adapt them to future events or developments. The interim report can include information that does not form part of accounting regulations. Such information is to be regarded as a supplement to, but not a substitute for, information prepared according to IFRS. Due to rounding, it is possible that some figures in this and other documents do not add up precisely to the stated sum, and that stated percentages do not reflect the absolute figures to which they relate. This document is a translation of a document originally prepared in German. Where differences occur, precedence is given to the original German version.

Publication date: 25 May 2023

Published by:

B·R·A·I·N

BRAIN Biotech AG

Darmstädter Straße 34 – 36

64673 Zwingenberg · Germany

phone +49 (0) 62 51 / 9331-0

fax +49 (0) 62 51 / 9331-11

email public@brain-biotech.com

website www.brain-biotech.com